摘要
目的:报告1例伴有HIP1/PDGFRB融合基因的不典型慢性增殖性髓系肿瘤,并就第4版WHO造血及淋巴组织肿瘤提出的新的一类伴PDGFRB基因异常髓系肿瘤进行文献综述。方法:患者脾大、乏力15年,病程中先后出现红细胞和血小板增多、巨脾、贫血、白细胞增多、单核细胞及嗜酸粒细胞增多。结果:骨髓细胞HIP1/PDGFRB融合基因检查为阳性,酪氨酸激酶抑制剂伊马替尼治疗有效。结论:酪氨酸激酶抑制剂伊马替尼治疗伴有HIP1/PDGFRB融合基因的髓系肿瘤临床效果满意。
Objective：To report a case of atypical myeloproliferative neoplasm with HIP1/PDGFRB gene,and to review myeloid neoplasms with eosinophilia and abnormalities of PDGFRB,a new kind of myeloid disorders in the revised 2008 WHO classification. Method：A patient was admitted because of fatigue and prominent splenomeg aly. In different stage she successively manifested erythrocytosis, thrombocytosis, splenomegaly, anemia, leukocyto sis monocytosis and eosinophilia. Result： The diagnosis was myeloid neoplasm with abnormality of PDGFRB. She has been treated with imatinib mesylate. Conclusion： Limatinib mesylate is effective treatment to myeloid neoplasms with eosinophilia and abnormalities of PDGFRB.
出处
《临床血液学杂志》
CAS
2012年第6期715-716,共2页
Journal of Clinical Hematology
